GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage...

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...

GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025...

GSK welcomes the Florida State Court's Daubert ruling excluding unreliable expert testimony, seeking dismissal of the Wilson case alleging ranitidine-prostate cancer link...

GSK plc welcome favorable jury verdict in Illinois, ruling out any liability for plaintiff's colorectal cancer linked to ranitidine use...

GSK plc and CureVac N.V. restructure their collaboration into a licensing agreement, enhancing mRNA vaccine development for influenza and COVID-19...

GSK's Omjjara (momelotinib) gains approval from Japan's MHLW for treating myelofibrosis, addressing anaemia, symptoms, and splenomegaly in patients...

GSK seeks appeal of recent Daubert ruling in Zantac litigation in Delaware Superior Court. Scientific consensus disputes claim of increased cancer risk...

GSK secures FDA approval for Arexvy in adults aged 50-59 at increased risk for RSV-LRTD. Clinical development ongoing, expanding vaccine benefits globally...

GSK plc announces positive results from DREAMM-8 trial at ASCO 2024, showing significant improvements in PFS for Blenrep combination therapy...

GSK plc celebrates favorable jury verdict in first Zantac trial, highlighting scientific consensus on ranitidine safety and ongoing defense against claims...